Compatibility and stability of valsartan in a solid pharmaceutical formulation
Valsartan (VAL) is a highly selective blocker of the angiotensin II receptor that has been widely used in the treatment of hypertension. Active pharmaceutical ingredient compatibility with excipients (crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose and titanium dioxide) is...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Livre |
| Publié: |
Universidade de São Paulo,
2013-12-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_6231eb24f5af4bfe8efbefb9a7921ee6 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Tamíris Amanda Júlio |e author |
| 700 | 1 | 0 | |a Igor Fernando Zâmara |e author |
| 700 | 1 | 0 | |a Jerusa Simone Garcia |e author |
| 700 | 1 | 0 | |a Marcello Garcia Trevisan |e author |
| 245 | 0 | 0 | |a Compatibility and stability of valsartan in a solid pharmaceutical formulation |
| 260 | |b Universidade de São Paulo, |c 2013-12-01T00:00:00Z. | ||
| 500 | |a 2175-9790 | ||
| 500 | |a 10.1590/S1984-82502013000400003 | ||
| 520 | |a Valsartan (VAL) is a highly selective blocker of the angiotensin II receptor that has been widely used in the treatment of hypertension. Active pharmaceutical ingredient compatibility with excipients (crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose and titanium dioxide) is usually evaluated in solid pharmaceutical development. Compatibility and stability can be evaluated by liquid chromatography. Studies were performed using binary mixtures of 1:1 (w/w) VAL/excipient; samples were stored under accelerated stability test conditions (40 ºC at 75% relative humidity). The results indicate that VAL is incompatible with crospovidone and hypromellose, which reduced the VAL content and gave rise to new peaks in the chromatogram due to degradation products. | ||
| 546 | |a EN | ||
| 690 | |a Valsartana | ||
| 690 | |a Valtasan | ||
| 690 | |a Hipertensão | ||
| 690 | |a Calorimetria Exploratória Diferencial | ||
| 690 | |a Cromatografia líquida de alto desempenho | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Brazilian Journal of Pharmaceutical Sciences, Vol 49, Iss 4, Pp 645-651 (2013) | |
| 787 | 0 | |n http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502013000400003&lng=en&tlng=en | |
| 787 | 0 | |n https://doaj.org/toc/2175-9790 | |
| 856 | 4 | 1 | |u https://doaj.org/article/6231eb24f5af4bfe8efbefb9a7921ee6 |z Connect to this object online. |